Inflammatix
Inflammatix is a pioneering molecular diagnostics company focused on reimagining diagnostics by 'reading' the patient’s immune system to deliver rapid results that improve patient care and reduce public health burdens. Its innovative tests, including the TriVerity™ Acute Infection and Sepsis Test, leverage proprietary biomarkers and advanced machine learning algorithms to provide clinicians with rapid, accurate, and holistic assessments of infection and illness severity. The company aims to enable precision medicine at the point of care, supporting early detection and treatment of infections and sepsis, which are major public health challenges. With FDA clearance for its TriVerity™ system and ongoing collaborations with military and healthcare institutions, Inflammatix is committed to transforming infectious disease diagnostics and improving patient outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
Inflammatix
540 Oakmead Pkwy, Sunnyvale, CA 94085
Patents
DNA sequences related to diagnosis and treatment of systemic inflammatory response syndrome
US-11104946-B2
View DetailsSystems and methods for transmitting pathogen related information and responding
US-8068991-B2
View Details
DNA sequences related to diagnosis and treatment of systemic inflammatory response syndrome
US-11104946-B2
View DetailsSystems and methods for transmitting pathogen related information and responding
US-8068991-B2
View DetailsProducts
Acute infection and sepsis mRNA host-response test system (cartridge + analyzer)
A point-of-care test system comprising a single-use cartridge assay and a benchtop sample-to-answer analyzer that measures a multi-gene host-response mRNA panel to report bacterial/viral likelihood and short-term illness severity in approximately 30 minutes.
Acute infection and sepsis mRNA host-response test system (cartridge + analyzer)
A point-of-care test system comprising a single-use cartridge assay and a benchtop sample-to-answer analyzer that measures a multi-gene host-response mRNA panel to report bacterial/viral likelihood and short-term illness severity in approximately 30 minutes.
Services
Design and run prospective, multicenter and interventional studies in emergency department settings, including use of investigational-device pathways and endpoints relevant to acute infection and sepsis care.
Development, training, tuning, and fairness assessment of ML classifiers for diagnostic and prognostic applications using host gene-expression data, including optimized thresholding and banding for clinical decision-making.
Assay development and laboratory-based analytical validation including precision, linearity, interference testing, and cross-platform concordance for multiplex host mRNA assays.
Consultative and programmatic support for regulatory submissions, quality management implementation (ISO-aligned), device permitting, and interactions with regulatory authorities.
Operational planning and execution support for scaling production of analyzers and single-use cartridges, supplier network development, and logistics planning for diagnostic commercialization.
Design and run prospective, multicenter and interventional studies in emergency department settings, including use of investigational-device pathways and endpoints relevant to acute infection and sepsis care.
Development, training, tuning, and fairness assessment of ML classifiers for diagnostic and prognostic applications using host gene-expression data, including optimized thresholding and banding for clinical decision-making.
Assay development and laboratory-based analytical validation including precision, linearity, interference testing, and cross-platform concordance for multiplex host mRNA assays.
Consultative and programmatic support for regulatory submissions, quality management implementation (ISO-aligned), device permitting, and interactions with regulatory authorities.
Operational planning and execution support for scaling production of analyzers and single-use cartridges, supplier network development, and logistics planning for diagnostic commercialization.
Expertise Areas
- Host-response diagnostics for acute infection and sepsis
- Point-of-care cartridge-based analyzer development
- Machine learning for clinical diagnostic classifiers
- Assay chemistry and multiplex mRNA measurement
Key Technologies
- Multi-gene host-response mRNA panels
- Isothermal amplification chemistries
- Multiplex RT-qPCR
- Cartridge-based sample-to-answer analyzers
News & Updates
Inflammatix announced FDA clearance for its TriVerity™ Test, a rapid immune response diagnostic for infection and sepsis.
The TIMED trial is designed to demonstrate the clinical utility of the TriVerity™ test in managing patients with suspected infections.
Inflammatix received the AACC Disruptive Technology Award for its rapid HostDx™ tests that read the immune system to improve diagnosis of infections and sepsis.
The TriVerity™ test received FDA Breakthrough Device designation in November 2023, recognizing its potential to improve diagnosis of infection and sepsis.
Inflammatix secured $102 million in Series D funding to support commercialization of its diagnostics.
Inflammatix announced FDA clearance for its TriVerity™ Test, a rapid immune response diagnostic for infection and sepsis.
The TIMED trial is designed to demonstrate the clinical utility of the TriVerity™ test in managing patients with suspected infections.
Inflammatix received the AACC Disruptive Technology Award for its rapid HostDx™ tests that read the immune system to improve diagnosis of infections and sepsis.
The TriVerity™ test received FDA Breakthrough Device designation in November 2023, recognizing its potential to improve diagnosis of infection and sepsis.
Inflammatix secured $102 million in Series D funding to support commercialization of its diagnostics.